ArticleJournal of the American Academy of Dermatology2020
Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy.
Article in Journal of the American Academy of Dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Disseminated Superficial Actinic Porokeratosis: A Systematic Treatment Review.American journal of clinical dermatology · 2025Pooled it
- Malignant Transformation in Porokeratosis Ptychotropica: A Systematic Review.Acta dermato-venereologica · 2024Pooled it
- Application of mevalonolactone prevents deterioration of epidermal barrier function by accelerating the lamellar granule lipid transport system.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2022Trial
- [2 % Simvastatin/2 % cholesterol cream in disseminated superficial actinic porokeratosis effectively and safely used long-term : Case report and retrospective survey of 14 patients].Dermatologie (Heidelberg, Germany) · 2026Article
- Lower Cholesterol and Antilipemic Medications are Associated with Disseminated Superficial Actinic Porokeratosis: A TriNetX Study.International journal of dermatology · 2026Article
- Efficacy and safety of topical statins for porokeratosis: a systematic review and practice-guided synthesis.Skin health and disease · 2026Review
- Long-term disease control of disseminated superficial actinic porokeratosis (DSAP) with simvastatin 2%/ cholesterol 2% cream.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- Transcriptomic and proteomic analysis of MVK variant sites in two subtypes of porokeratosis.Journal of applied genetics · 2026Article
- A Case of Refractory Giant Porokeratosis, Treated With a New Treatment Approach Consisting of Ablative COClinical case reports · 2026Article
- A 12-year expanding pink plaque on the chest.JAAD case reports · 2026Article
- Systematized Linear Porokeratosis With Palmoplantar and Nail Involvement: A Rare Presentation.Cureus · 2026Article
- Identification of two novelFrontiers in medicine · 2026Article
- Successful Treatment of Linear Porokeratosis with Ivarmacitinib in an Adolescent: A Case Report.Clinical, cosmetic and investigational dermatology · 2026Article
- Dysregulated cholesterol metabolism in genodermatoses: implications for systemic disease and therapeutic strategies.Frontiers in cell and developmental biology · 2026Review
- Topical Treatments for Rare Genetic Dermatological Diseases: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Systematized Linear Porokeratosis, with Underlying Mevalonate Kinase Mutation, Treated with a Combination of Radiosurgery and Oral Acitretin.Indian dermatology online journal · 2025Article
- Porokeratosis ptychotropica mimicking a herpes simplex virus infection.JAAD case reports · 2025Article
- From a Gene Mutation to Pathology and Targeted Therapy in a Patient with Therapy-resistant Porokeratosis.Acta dermato-venereologica · 2025Article
- Article
- Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
backgroundPorokeratosis is associated with mevalonate pathway gene mutations. Therapeutic options are few and often limited in efficacy. We hypothesized that topical therapy that aims to replenish cholesterol, an essential mevalonate pathway end-product, and block the accumulation of mevalonate pathway toxic metabolites could alleviate porokeratosis.
objectiveTo study the efficacy of topical cholesterol/lovastatin in different variants of porokeratosis.
methodsWe enrolled a series of 5 porokeratosis patients,1 with disseminated superficial actinic porokeratosis, 2 with porokeratosis palmaris et plantaris disseminata, and 2 with linear porokeratosis. Patients were genotyped before initiation of therapy. Patients then applied topical cholesterol/lovastatin twice daily to a unilaterally defined treatment area for up to 3 months. The response was evaluated and patients photographed at every visit.
resultsThree patients had MVD mutations, and 2 patients had PMVK mutations. Treatment with topical cholesterol/lovastatin (but not cholesterol alone) resulted in near complete clearance of disseminated superficial actinic porokeratosis lesions after 4 weeks of therapy and moderate improvement of porokeratosis palmaris et plantaris disseminata lesions and linear porokeratosis lesions. There were no adverse events. LIMITATIONS: Case series design with a small number of patients.
conclusionTopical cholesterol/lovastatin is an effective and well-tolerated therapy for porokeratosis that underscores the utility of a pathogenesis-based therapy that replaces deficient end products and prevents accumulation of potentially toxic precursors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.